Anbio Biotechnology (NASDAQ:NNNN) Stock Short Interest Drops 42.4%

Anbio Biotechnology (NASDAQ:NNNN) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 31,124 shares, a decline of 42.4% from the September 30th total of 54,022 shares. Based on an average trading volume of 46,624 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.0% of the shares of the stock are sold short.

Anbio Biotechnology Trading Down 9.7%

NASDAQ:NNNN traded down $0.36 on Friday, hitting $3.36. 39,020 shares of the company’s stock were exchanged, compared to its average volume of 56,927. The firm has a 50-day moving average price of $5.47 and a 200-day moving average price of $16.73. Anbio Biotechnology has a 52 week low of $3.09 and a 52 week high of $44.73.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Hold rating. According to MarketBeat, Anbio Biotechnology presently has an average rating of “Hold”.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.